Drug intelligence / Profile preview

SPEAACT-2

Development stage: Preclinical
Lead developer: Sunstate Biosciences
Modality: Small Molecules, Recombinant Proteins and Enzymes

Overview

SPEAACT-2 is a preclinical-stage therapeutic candidate developed by Sunstate Biosciences for the treatment of HER2-positive breast cancer and gastric cancer. The drug consists of a small molecule RNA polymerase inhibitor encapsulated within a protein shell using the company's proprietary Single Protein Encapsulation (SPE) technology. This platform is designed to improve the delivery and therapeutic index of the small molecule payload. By targeting RNA polymerase, SPEAACT-2 inhibits the transcription of genetic information into RNA, thereby disrupting essential cellular processes in cancer cells and promoting tumor regression.

Other names: SPEAACT-2SPEAACT2SPEAACT 2

Targets

RNAP (Bacterial dna-dependent RNA polymerase)

Beyond the preview

Go deeper on SPEAACT-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPEAACT-2.

Explore the full profile